(2S,5R,6R)-6-[(2-carboxy-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2S,5R,6R)-6-[[3-(2,3-dihydro-1H-inden-5-yloxy)-3-oxo-2-phenylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: (2S,5R,6R)-6-[(2-carboxy-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2S,5R,6R)-6-[[3-(2,3-dihydro-1H-inden-5-yloxy)-3-oxo-2-phenylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
• 化学式: C43H44N4O12S2
• 分子量: 873.0
• InChiKey: JWSJAZWSTUAXSU-VRGLQCRPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.98
• 重原子数：
  61
• 可旋转键数：
  12
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  288
• 氢给体数：
  5
• 氢受体数：
  14

文献信息

• Implants and methods for treating inflammation-mediated conditions of the eye
  申请人：Allergan, Inc.

  公开号：US10206934B2

  公开（公告）日：2019-02-19

  Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.

  描述了治疗由炎症介导的眼部疾病的方法，包括：将生物可塑植入物植入个体的眼部玻璃体，该植入物包含类固醇抗炎剂和生物可塑聚合物，其中植入物将药剂输送到玻璃体的量足以在约 48 小时内达到至少相当于约 0.05 μg/ml 地塞米松的浓度，并在至少约三周内保持至少相当于约 0.03 μg/ml 地塞米松的浓度。
• ANTIBIOTIC METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS
  申请人：The University of Chicago

  公开号：EP2916653A1

  公开（公告）日：2015-09-16
• EP2969003A1
  申请人：——

  公开号：EP2969003A1

  公开（公告）日：2016-01-20
• METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS
  申请人：THE UNIVERSITY OF CHICAGO

  公开号：US20160120852A1

  公开（公告）日：2016-05-05

  Compositions and methods are provided for treating or inhibiting a bacterial infection involving at least one antibiotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a beta lactam. In further embodiments, the antibiotic is oxacillin. In additional embodiments, the potentiating compound is an inhibitor of vraSR operon expression. In specific embodiments, the bacterial infection involves an antibiotic-resistant bacteria.
• IMPLANTS AND METHODS FOR TREATING INFLAMMATION-MEDIATED CONDITIONS OF THE EYE
  申请人：Allergan, Inc.

  公开号：US20180021352A1

  公开（公告）日：2018-01-25

  Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodihle polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.